Clinical Trials Directory

Trials / Completed

CompletedNCT04141371

Molar Sodium Lactate Filling in Severe Meningeal Hemorrhage

Effect of Molar Sodium Lactate Filling on Cerebral Hemodynamics in Patients With Severe Meningeal Hemorrhage Multicenter Randomized Study

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
3 (actual)
Sponsor
Centre Hospitalier Universitaire de Nice · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Subarachnoid hemorrhage by aneurysmal rupture is a serious condition associated with a high mortality rate. Among the complications presented by these patients, vasospasm is one of the main causes of secondary aggravation, in particular the appearance of delayed neurological deficits following the induced cerebral ischemia. Classically occurring between the 4th and 12th day, with a peak on D7, its prevention is currently often ineffective. In recent years, many studies have shown that sodium lactate could be an interesting product for neuroprotection. In addition to an anti-osmotic effect that has been demonstrated by our team in the context of post-traumatic intracranial hypertension, a metabolic action has also been observed in periods of metabolic attacks induced by brain attacks. Recently, a vasodilatory action of sodium lactate has been observed from an experimental and clinical point of view. The purpose of this work is to observe the effect of sodium lactate, compared to placebo, on cerebral hemodynamics measured by perfusion CT (Mean Transit Time MTT) in a population of patients with hemorrhage under the arachnoid. This work is the preliminary work of a study that will investigate the potential preventive protective effect of sodium lactate on the incidence of vasospasm.

Conditions

Interventions

TypeNameDescription
DRUGMolar Sodium Lactatedaily 3-hour infusion of sodium molar lactate during the vasospasm period
DRUGphysiological serumdaily saline infusion over 3 hours during the vasospasm period

Timeline

Start date
2022-02-14
Primary completion
2022-05-05
Completion
2024-06-07
First posted
2019-10-28
Last updated
2025-03-19

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04141371. Inclusion in this directory is not an endorsement.